A study has found that there is a dose-dependent relationship between increased risk for depression and cardiometabolic diseases.

Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); ...

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

Researchers conducted a population-based retrospective cohort study using data from the TriNetX Analytics ... the Journal of ...

Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.

Australia: A recent study published in Clinical Infectious Diseases has shown that the current use of integrase strand ...

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

Study limitations include the retrospective design, incomplete data on anticitrullinated peptide antibody testing and X-rays due to cost constraints, and potential recall bias from self-reported ...

Good morning, and welcome to the Wave Life Sciences Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

Five-year follow-up results from cohort 1 of the Phase 3 SEQUOIA study showed sustained progression-free survival (PFS) ...